NutriStack
Mesalamine and Saccharomyces Boulardii, a synergy.
Saccharomyces boulardii has limited human evidence as an add-on during mesalamine maintenance for mild-to-moderate ulcerative colitis flare symptoms. A small pilot trial reported clinical remission in many completers, but controlled confirmation is limited. Treat this as an emerging adjunct, not a core ulcerative colitis therapy.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Mesalamine and Saccharomyces Boulardii
- Pair type
- Synergy
- Evidence (highest tier)
- Emerging
- Source citations
- 2 sources
- Stack Score effect
- +2 to your Stack Score (per scored synergy row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Synergy · Emerging evidence
Synergy
What is happening. Saccharomyces boulardii has limited human evidence as an add-on during mesalamine maintenance for mild-to-moderate ulcerative colitis flare symptoms. A small pilot trial reported clinical remission in many completers, but controlled confirmation is limited. Treat this as an emerging adjunct, not a core ulcerative colitis therapy.
Mechanism. Mesalamine reduces colonic mucosal inflammation through topical anti-inflammatory effects. Saccharomyces boulardii may support barrier function, reduce pathogen-mediated inflammation, and alter gut immune signaling, producing a complementary but less proven effect.
Recommendation. If you try Saccharomyces boulardii with mesalamine, keep your prescription regimen unchanged and reassess after about 4 to 8 weeks. Avoid it if you are severely immunocompromised, critically ill, or have a central venous catheter because rare bloodstream infections have been reported with probiotic yeasts.
Sources (2)
- Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15(6):697-698. PMID 12840682
- Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11):1202-1209.e1. PMID 19631292
Stack Score
How this pair moves the number.
Effect on the composite score
If both Mesalamine and Saccharomyces Boulardii are in the same stack, this pair applies +2 to your Stack Score (per scored synergy row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.